Approval · Notice of Compliance 34699 · 2025
OZEMPIC: Notice of Compliance 34699
Issued January 15, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34699
- Date
- January 15, 2025
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in the drug substance process /
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OZEMPIC | Not yet assigned | — |
Medicinal ingredients
- SEMAGLUTIDE 2 MG per 1.5ML
- SEMAGLUTIDE 8 MG per 3ML
- SEMAGLUTIDE 2 MG per 3ML
- SEMAGLUTIDE 4 MG per 3ML